Options mapped
Esophageal cancer: options by country
Treatment options for Esophageal cancer mapped across 7 countries — covering clinical trials, immunotherapy, radiation and surgery — each linking to its regulator, HTA, or guideline source, with questions to bring to your care team. Options, not recommendations.
Options mappedSolid tumorLast checked June 2026
Options by country
Treatments by country
Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.
United States
- nivolumab (Opdivo)[1]FDA-approvedafter prior fluoropyrimidine- and platinum-based chemotherapy. · FDA approval notice supports the 2020 post-chemotherapy ESCC indication; current formulation/route and label details should be checked in the latest prescribing information. Confidence/conflicts: high for FDA approval notice; no conflict identified.
European Union
- nivolumab (Opdivo) monotherapy[2]EMA authorisedafter prior fluoropyrimidine- and platinum-based combination chemotherapy. · EMA central authorisation only; country-specific access and reimbursement remain separate checks. Confidence/conflicts: high for EMA central indication; local reimbursement unverified. No conflict identified.
- nivolumab (Opdivo) plus fluoropyrimidine- and platinum-based combination chemotherapy[2]EMA authorisedtumour-cell PD-L1 expression >= 1%; first-line unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. · EMA central authorisation does not establish national reimbursement, and the PD-L1 threshold is source-stated. Confidence/conflicts: high for EMA central indication; local reimbursement unverified. No conflict identified.
- nivolumab (Opdivo) plus ipilimumab (Yervoy)[2]EMA authorisedtumour-cell PD-L1 expression >= 1%; first-line unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. · EMA central authorisation does not establish country-specific reimbursement. The source specifies tumour-cell PD-L1 expression >= 1% for this indication. Confidence/conflicts: high for EMA central indication; local reimbursement unverified. No conflict identified.
- pembrolizumab (Keytruda) plus platinum- and fluoropyrimidine-based chemotherapy[3]EMA authorisedPD-L1 CPS >= 10; first-line locally advanced unresectable or metastatic oesophageal carcinoma. · EMA central authorisation does not establish Germany/France reimbursement or local hospital access. PD-L1 CPS threshold is part of the stated indication. Confidence/conflicts: high for EMA central indication; Germany/France reimbursement not verified in this finding. No conflict identified.
United Kingdom
- definitive/radical chemoradiotherapy; chemoradiotherapy before surgical resection; palliative or high-dose-field chemoradiotherapy depending setting[4]NICE recommendedT1bN0 squamous disease; resectable non-metastatic squamous disease; non-metastatic disease not suitable for surgery. · NICE requires discussion of options and suitability; radiation-field feasibility and surgical suitability are clinical/MDT determinations. Confidence/conflicts: high for NICE guideline wording; individual suitability not inferred. No conflict identified.
- nivolumab (Opdivo) plus fluoropyrimidine- and platinum-based combination chemotherapy[5]NICE recommendedPD-L1 expression level >= 1%; untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. · NICE explicitly positions this when pembrolizumab plus chemotherapy is not suitable and includes a commercial-arrangement condition. This is not a recommendation for all oesophageal cancer histologies. Confidence/conflicts: high for NICE recommendation; devolved/private access outside NICE context not verified. No conflict identified.
- open or minimally invasive oesophagectomy; two-field lymph node dissection when performing curative oesophagectomy[4]NICE recommendedsurgical treatment / curative oesophagectomy context. · NICE frames these as specialist MDT and surgical-unit decisions, not blanket eligibility. Suitability depends on stage, location, histology, fitness, and MDT judgement. Confidence/conflicts: high for NICE guideline wording; local surgical suitability not inferred. No conflict identified.
- pembrolizumab (Keytruda) plus platinum- and fluoropyrimidine-based chemotherapy[6]ApprovedPD-L1 CPS >= 10; untreated locally advanced unresectable or metastatic oesophageal carcinoma. · NICE recommendation includes a company commercial-arrangement condition and is an NHS England/Wales technology-appraisal context; the HER2-negative gastro-oesophageal junction adenocarcinoma part was updated/replaced by TA997. Confidence/conflicts: high for NICE recommendation; devolved/private access outside NICE context not verified. No conflict identified.
Japan
- nivolumab (Opdivo)[7]PMDA-approved (Japan)not required by PMDA discussion; PMDA notes PD-L1 selection was not necessary for this post-chemotherapy nivolumab setting; after prior fluoropyrimidine- and platinum-based chemotherapy. · PMDA English translation is reference material; Japanese original takes precedence. PMDA notes clinical studies enrolled patients categorized as squamous cell carcinoma, with non-squamous use requiring physician judgement based on the evidence context. Confidence/conflicts: medium-high; PMDA supports the post-chemotherapy esophageal cancer indication but notes the enrolled clinical population was squamous-cell. No conflict identified. Availability/reimbursement outside the approving regulator not established.
- nivolumab (Opdivo)[8]PMDA-approved (Japan)not achieved pathological complete response (pCR) after neoadjuvant therapy; adjuvant therapy after neoadjuvant therapy in patients without pCR. · PMDA English translation is reference material; Japanese original takes precedence. Source does not establish reimbursement or hospital formulary access. Confidence/conflicts: high for PMDA review-report indication; current Japanese package insert and reimbursement not checked in this finding. No conflict identified.
- pembrolizumab (Keytruda)[9]PMDA-approved (Japan)PD-L1 positive; after progression following cancer chemotherapy. · PMDA English translation is reference material; Japanese original takes precedence. The source is a review report and does not establish reimbursement or local hospital formulary status. Confidence/conflicts: high for PMDA review-report indication; current Japanese package insert and reimbursement not checked in this finding. No conflict identified.
Korea
- nivolumab (Opdivo) plus fluoropyrimidine- and platinum-containing chemotherapy[10]MFDS-approved (Korea)tumour-cell PD-L1 expression >= 1%; first-line unresectable advanced or metastatic esophageal squamous cell carcinoma. · This is a manufacturer announcement citing MFDS approval, not an MFDS-primary label or HIRA reimbursement source. Current Korea label and reimbursement status remain follow-up gaps. Confidence/conflicts: medium; MFDS approval is manufacturer-attributed and primary label/reimbursement were not fetched. No conflict identified.
- nivolumab (Opdivo) plus ipilimumab (Yervoy)[10]MFDS-approved (Korea)tumour-cell PD-L1 expression >= 1%; first-line unresectable advanced or metastatic esophageal squamous cell carcinoma. · This is a manufacturer announcement citing MFDS approval, not an MFDS-primary label or HIRA reimbursement source. Current Korea label and reimbursement status remain follow-up gaps. Confidence/conflicts: medium; MFDS approval is manufacturer-attributed and primary label/reimbursement were not fetched. No conflict identified.
China
- pembrolizumab (Keytruda) monotherapy[11]ApprovedPD-L1 CPS >= 10 by a fully validated test; second-line / following failure of one prior line of systemic therapy. · This is a manufacturer announcement attributing approval to NMPA, not an NMPA-primary label page. China label wording, reimbursement, and current availability need primary-source confirmation before patient-facing reuse. Confidence/conflicts: medium; NMPA approval is company-attributed and primary China label was not fetched. No conflict identified.
- sintilimab (Tyvyt) plus cisplatin/paclitaxel or cisplatin/5-fluorouracil chemotherapy[12]NMPA-approved (China)not restricted by PD-L1 in the source's stated approval wording; first-line treatment. · This is a company/PR Newswire announcement attributing approval to NMPA CDE, not an NMPA-primary label. It states ORIENT-15 benefit regardless of PD-L1 expression, but local label and reimbursement should be checked directly. Confidence/conflicts: medium; NMPA approval is company-attributed and primary China label was not fetched. No conflict identified.
Sources
- U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- National Institute for Health and Care Excellence (NICE) — national guideline · national guideline
- National Institute for Health and Care Excellence (NICE) — national HTA/guideline recommendation · national HTA/guideline recommendation
- National Institute for Health and Care Excellence (NICE) — national HTA/guideline recommendation · national HTA/guideline recommendation
- Pharmaceuticals and Medical Devices Agency (PMDA) — regulator review report · regulator review report
- Pharmaceuticals and Medical Devices Agency (PMDA) — regulator review report · regulator review report
- Pharmaceuticals and Medical Devices Agency (PMDA) — regulator review report · regulator review report
- Ono Pharmaceutical — manufacturer approval announcement citing MFDS · manufacturer approval announcement citing MFDS
- Merck — manufacturer approval announcement citing NMPA · manufacturer approval announcement citing NMPA
- Innovent Biologics / PR Newswire — manufacturer approval announcement citing NMPA CDE · manufacturer approval announcement citing NMPA CDE
This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked June 2026.
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
In clinical trials
- pembrolizumab (Keytruda) combination-therapy umbrella substudy arms including I-DXd, fluoropyrimidine/oxaliplatin chemotherapy, sacituzumab tirumotecan, and rescue medication as listed in the registryClinical trial · NCT06780111Clinical trialTrial only (NCT06780111)Thailand · esophageal cancer umbrella combination-therapy substudy; exact line of therapy should be confirmed in the full protocol. · Registry evidence only; not proof of Thai FDA approval, routine availability, reimbursement, or individual eligibility. Trial arms and site status require protocol and site confirmation. Confidence/conflicts: high for registry status and Thailand site listing; no regulator approval implied. No conflict identified. ClinicalTrials.gov — clinical-trial registry
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked June 2026.
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
- Has prior fluoropyrimidine- and platinum-based chemotherapy been received?
- Is the diagnosis esophageal squamous cell carcinoma?
- Which nivolumab formulation and schedule are locally intended?
- Has PD-L1 CPS testing been performed and documented as CPS >= 10?